anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. An improved method of freeze drying an aqueous solution of recombinant activated protein C, comprising conducting such freeze drying at an ionic strength of greater than 150mM and a pH of about 5.5 to less than 6.3. 2. The method of claim 1 wherein protein C is human activated protein C. 3. The method of claim 2 wherein the pH is from 5.6 to 6.2. 4. The method of claim 3 wherein such solution comprises sodium chloride. 5. The method of claim 4 wherein the sodium chloride concentration is 200mM to 1000mM. 6. The method of claim 1 wherein the pH is buffered with sodium citrate. 7. A preparation of activated protein C obtainable by freeze drying a solution of activated protein C having an ionic strength of greater than 150mM and a pH of about 5.5 to less than 6.3, in the absence of a denaturing agent, histidine, lysine hydrochloride or albumin. 8. An aqueous solution of recombinant activated protein C, comprising recombinant activated protein C; said solution having an ionic strength of greater than 150mM and a pH of about 5.5 to less than 6.3 having less than 10% des(1-9) activated protein C and des(1-10) activated protein C by combined weight. 9. A pharmaceutical formulation comprising recombinant activated protein C; said formulation having less than about 10% des(1-9) activated protein C and des(1-10) activated protein C by combined weight. 10. A pharmaceutical formulation of claim 9; said formulation having less than about 5% des(1-9) activated protein C and des(1-10) activated protein C by combined weight.
Those in the intervention group will be encouraged to sip a solution of sodium bicarbonate (1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved into 250ml of water; if the entire 250mL is consumed, another 1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved in 250mL of water will be provided to the patient) throughout labour with other drinks as desired. All other care will remain the same.
Purpose: This study aimed to compare the time-course changes of exercise-induced muscle damage (EIMD) levels in the long head of biceps brachii (LHB) and short head of the biceps brachii (SHB) using echo intensity (EI) and to determine the efficiency of the gray level co-occurrence matrix (GLCM) texture parameters. Methods: The participants performed 30 maximal eccentric contractions of the elbow flexor. Along with muscle damage indicators, including circumference, range of motion, muscle soreness, and maximal voluntary isometric contraction (MVIC), the EI and GLCM texture features of the LHB and SHB was also assessed using B-mode ultrasonography. All measurements were assessed pre- and immediately post-exercise and after 24, 48, 72, and 96 h. Results: The muscle damage indicators indicated significant changes after the eccentric contractions (p < 0.01 for circumference, range of motion, muscle soreness, and MVIC). The EI of LHB significantly increased following the contractions (p < 0.01), but that of SHB did not (p > 0.05). In contrast, for the GLCM texture parameters, there were significant changes in the SHB (p < 0.01 for homogeneity, energy, and entropy). Conclusion: Thus, this study demonstrated that EIMD severity is different between LHB and SHB even within the same muscle. In the GLCM features, the time course of SHB after eccentric contraction revealed different patterns compared with those of LHB. Therefore, even if there are no changes in EI within a target muscle following muscle contractions, new information on muscle quality can be obtained through GLCM analysis.
The present invention provides a dental composition comprising a curable blend of one or more polythiol compounds and one or more polyvinyl compounds; where one or both compounds are oligomers. In one aspect, the polythiol compounds are polythiol oligomers formed by prepolymerization of polyvinyl monomers in the presence of an excess of polythiol monomers. In another aspect, the polyvinyl compounds are polyvinyl oligomers formed by prepolymerization of polythiol monomers in the presence of an excess of polyvinyl monomers. The dental composition may further comprise one or more fillers or photoinitiators known in the art. The invention also comprises methods of making a dental prosthesis comprising the composition described above. Use of the thiol-ene oligomeric system results in cured (polymerized) dental compositions having improved physical properties, including low-shrinkage properties and reduced shrinkage induced-stress, enhanced double bond conversion percentage, and reduced odor.
The invention discloses a traditional Chinese medicine pill of dark plum pill for treating colonic ulcer, which is prepared from the following components in parts by weight: the traditional Chinese medicine composition is prepared from 13 traditional Chinese medicines of kudzuvine root, Chinese angelica, coptis, costustoot, immature bitter orange, dark plum fruit, largehead atractylodes rhizome, pilose asiabell root, Indian buead, honey-fried licorice root, white paeony root, dahurian patrinia herb, ash bark and the like. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in regulating intestinal tract physiological function, invigorating qi, invigorating spleen, clearing away heat and toxic materials, regulating stomach function, clearing intestine, regulating qi and blood, promoting circulation of qi, removing food stagnation, relieving exterior syndrome, clearing away heat, invigorating stomach and intestine, removing necrotic tissue, promoting granulation, improving intestinal mucosa function, repairing ulcer, healing, and enhancing oxidation resistance. 4. Can improve clinical signs of patients and has repairing effect on colonic erosion ulcer.
The invention discloses a contract sharing and self-attention-based COVID-19 focus prediction system. The system comprises a medical record encryption module, a focus segmentation module based on an attention mechanism, a focus prediction module, a combination scoring module and a permission control module. The focus segmentation and prediction module consists of a convolution operation unit, an attention calculation unit, a pooling unit, a pixel fusion unit and a classification small module. In order to realize the high-precision segmentation task of the image, the system adopts a U-Net deep learning network architecture based on SwinT blocks. SwinT block is a multi-scale window interaction attention mechanism that better models features of different scales in an image by partitioning the image features into different windows and interacting between the windows using a self-attention mechanism. The framework combines the characteristics of U-Net and Swin transducer, so that more accurate results can be obtained when image segmentation and prediction are carried out, and the accuracy of the system on the prediction of the COVID-19 focus is improved.
BACKGROUND: CHANTER (Cerebellar Hippocampal and Basal Nuclei Transient Edema with Restricted diffusion) is a recently described syndrome occurring in the context of drug abuse. While clinical findings are rather unspecific (disorientation, unresponsiveness), MR imaging (MRI) discloses a characteristic pattern (restricted diffusion in the basal ganglia and hippocampi, cerebellar oedema and haemorrhage), allowing for timely diagnosis before complications such as cerebellar swelling and herniation do occur. Here we report a case of CHANTER primarily based on imaging findings, as there was no evidence of drug abuse on admission.
CASE PRESENTATION: A 62-year-old Patient was admitted to our hospital after being unresponsive at home. Prehospital intubation was performed, which limited neurological assessment. Under these circumstances no obvious symptoms could be determined, i.e. pupils were isocoric and responsive, and there were no signs of seizures. While the initial CT scan was unremarkable, the subsequent MRI scan showed a distinct imaging pattern: moderately enhancing areas in the basal ganglia and hippocampi with diffusion restriction, accompanied by cerebellar haemorrhage and oedema (Figs. 1 and 2). A comprehensive clinical and laboratory work-up was performed, including drug screening, spinal tap, Holter ECG, echocardiography and EEG. The only conspicuous anamnestic finding was a chronic pain syndrome whose medication had been supplemented with opioids two months previously. The opioid medication was discontinued, which led to a rapid improvement in the patient's clinical condition without any further measures. The patient was able to leave the intensive care unit and was discharged 10 days after admission without persistent neurological deficits.
CONCLUSION: Familiarity with typical MRI patterns of toxic encephalopathy in patients from high-risk groups, such as drug abusers, is crucial in emergency neuroradiology. In the presence of typical MRI findings, CHANTER syndrome should be included in the differential diagnosis, even if there is no history of drug abuse, to avoid delay in diagnosis and treatment.
PURPOSE: To explore the association between chronic prostatitis (CP) and the subsequent development of benign prostatic hyperplasia (BPH).
METHODS: Data analyzed were medical claims of Taiwan's National Health Insurance program. From 2010 to 2017, 3571 patients ≧20 years with CP diagnosed by certified urologists were enrolled. Patients with past BPH diagnosis and diagnosis of prostate cancer, inguinal hernia, interstitial cystitis, and urethritis in the past and within one year after the first CP diagnosis were excluded. Age-matched controls were randomly selected from all non-CP individuals of the same exclusion criteria in the study period with a CP/non-CP ratio of 1:4. The follow-up was made from the first CP diagnosis to death or the end of 2018. The endpoint was the newly diagnosed BPH. Cox proportional hazard regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of BPH in association with CP.
RESULTS: Over a maximum of 8 years of follow-up, 287 (8.03%) and 258 (0.43%) BPH events were noted for the CP and non-CP group, respectively, representing a covariate adjusted HR (aHR) of 4.30 (95% CI, 3.61-5.13). Younger patients tended to suffer from higher aHRs, especially those aged 20-39 years (aHR: 11.45, 95% CI, 5.12-25.64).
CONCLUSION: The Taiwan national health database indicated that CP patients had a significantly higher risk of developing BPH later than non-CP patients. Interestingly, the younger the CP is diagnosed (under 40), the greater the risk.
Research on the effects of physiotherapeutic interventions in children with CP has grown expansively, and shows a wide diversity of techniques and concepts that are used in variable intensity. Until now there is no consensus on the optimal intensity of these interventions to have a positive impact on the activity and participation level of these children. A recent systematic review and meta-analysis already showed evidence for the effect of intensive training of hand function in children with CP, including short bursts of highly intensive therapy. In contrast, studies on the effect of intensive therapy of gross motor function were limited, and training was performed at a lower intensity during a longer period, resulting in effects that are more inconclusive. Moreover, none of the reviewed studies included improvement of trunk control as one of their treatment goals, although it is known that most children with CP experience some problems with trunk control, to a variable extent.

This research project has two aims, i.e. 1) investigating the effect of intensive therapy camps on qualitative and quantitative parameters of lower limbs and trunk; and 2) comparing the effect of two therapeutic approaches, namely a functional approach versus a more qualitative-functional approach on these parameters.
Following standard clinical care consisting of serial endoscopic dilation to achieve an esophageal diameter of at least 10 mm, subjects will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses which is the current standard of care. A relapse will be considered if a patient developed solid food dysphagia at least once a week.
In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
Proteus syndrome is a rare segmental overgrowth disorder caused by a somatic gain of function mutation, c.49GA, p.Glu17Lys) in the oncogene AKT1, encoding the AKT1 kinase . The disorder is progressive, with high morbidity and mortality - there are very few living adults with this disease. Tissues and cell lines from patients with Proteus syndrome harbor admixtures of mutant alleles that ranged from \<1% to approximately 50%. This mutation causes constitutive activation of AKT1, through Ser473 and Thr308 phosphorylation. This activation stimulates the AKT/PI3K pathway, mediating processes including increased cell proliferation and decreased apoptosis. The progressive nature of the disorder and the mechanism of disease (gain of function) make AKT1 an excellent target for therapeutics, specifically repression. The AKT/PI3K pathway is mutated in numerous cancers as well. Because it is commonly mutated in cancer, pharmaceutical companies are interested in targeting this molecule with inhibitors. Indeed, Proteus syndrome can be considered a simple model for cancer therapeutics, as these patients are known to harbor only a single activating mutation instead of the hundreds or thousands that are mutated in cancers. ArQule Inc., a wholly owned subsidiary of Merck \& Co., has developed a small molecule, miransertib (MK-7075) that effectively inhibits AKT, with the lowest IC50 for AKT1 (as compared to AKT2 or AKT3, and orders of magnitude lower for other kinases). This agent has undergone significant development with animal toxicity studies and is currently in phase I trials in patients with different types of cancer. In addition, we have performed in vitro testing with miransertib in cells from patients with Proteus syndrome and demonstrated reduction in AKT1 phosphorylation at doses in the range of achievable blood levels in humans with low toxicity. Because Proteus syndrome is a chronic disease, typical approaches to defining the recommended phase II dose by determining the maximum tolerated dose (MTD) are not appropriate it is unreasonable to propose that patients would tolerate significant side effects for prolonged time periods. As an initial trial for this disease, we propose a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome. The recommended phase II dose will be determined based on the tolerability of miransertib in children and adults with Proteus syndrome and measures of drug levels in plasma and affected tissues in patients with Proteus syndrome and measures of tissue phosphorylation of AKT1. We hypothesize that the recommended dose of miransertib will be substantially below that of doses used in patients with cancer and that this will lead to a highly favorable risk-benefit ratio on which we can base future efficacy studies.
Sarcopenia is a progressive age-related muscle disease characterized by low muscle strength, quantity and quality, and low physical performance. The clinical overlap between these subphenotypes (reduction in muscle strength, quantity and quality, and physical performance) was evidenced, but the genetic overlap is still poorly investigated. Herein, we investigated whether there is a genetic overlap amongst sarcopenia subphenotypes in the search for more effective molecular markers for this disease. For that, a Bioinformatics approach was used to identify and characterize pleiotropic effects at the genome, loci and gene levels using Genome-wide association study results. As a result, a high genetic correlation was identified between gait speed and muscle strength (rG=0.5358, p=3.39 × 10-8). Using a Pleiotropy-informed conditional and conjunctional false discovery rate method we identified two pleiotropic loci for muscle strength and gait speed, one of them was nearby the gene PHACTR1. Moreover, 11 pleiotropic loci and 25 genes were identified for muscle mass and muscle strength. Lastly, using a gene-based GWAS approach three candidate genes were identified in the overlap of the three Sarcopenia subphenotypes: FTO, RPS10 and CALCR. The current study provides evidence of genetic overlap and pleiotropy among sarcopenia subphenotypes and highlights novel candidate genes and molecular markers associated with the risk of sarcopenia.
The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
Curing HCV in Incarcerated Patients (CHIP) is a 1-year demonstration project that will be conducted in the San Francisco County Jails. Jail settings can provide an optimal opportunity to screen for HCV, initiate curative treatment, and link patients to community HCV providers to complete their treatment. This demonstration project will be funded by the Gilead's Investigator Sponsored Research. The purpose is to assess the feasibility of treating inmates with the FDA approved combination oral treatment, sofosbuvir/velpatasvir, Epclusa®. The San Francisco Department of Public Health's Jail Health Services will treat 100 patients. Intensive patient navigators will be an essential component for treatment to ensure medication adherence and achieve SVR for those who are discharged from jail prior to HCV treatment completion. Navigators will provide short-term case management services by linking patients to medical and social support services. This demonstration project will be facilitated by the Jail Health Services' HIV \& Integrated Services (formerly Forensic AIDS Project).
The invention relates to a porin gene from Campylobacter jejuni [SEQ ID NO:3]. The gene has been designated porA and is 1275 bp in length and expresses a protein of 45.6 kDa having a pI of 4.44 [SEQ ID NO:2]. The sequencing and cloning of the gene makes possible various medical and industrial uses. For examples, knowledge of the DNA code makes it possible to design DNA probes for identification of the gene in samples for testing. A positive result indicates the presence of the gene in the sample and is a strong indicator of the presence of C. jejuni. Such probes can also be used to isolate the corresponding cDNA, that may then be amplified by polymerase chain reaction. The development of DNA probes based on a known sequence is a known procedure that is familiar to persons skilled in the art and it will be possible for such persons to develop suitable probes without undue experimentation. Normally, such probes would consist of at least 15 consecutive nucleotides from the cDNA sequence.
A biodegradable delivery device is disclosed that is implanted into patients to provide an extended release of one or more active pharmaceuticals for a therapeutic purpose. The delivery device comprises of: 1) an outer sheath that is composed of an inert biodegradable material that prevents the direct interactions of the core(s) with patient tissues and also facilitates the homogenous access of solvent to the surface area of the core to enable predictable core ingredient dissolution, depletion and safe and effective concentrations. 2) A Primary Core comprising one or more active ingredients plus excipients, including markers, that biodegrades and elutes all its ingredients before the sheath degrades. 3) A Secondary Core at the geometric center of the Primary core comprising a marker (including an active pharmacological or inactive ingredient that can be detected by bioanalysis, or a radio-opaque marker) that can signal when the secondary core is exposed, and excipients, which biodegrades and elutes its ingredients. 4) All elements have a marker excipient that renders the device observable remotely, including by x-ray detecting barium sulfate. The Secondary Core has a marker signal that can be distinguished from the Primary Core and Outer sheath.
Cumulative evidence has showed the deficits of inhibitory control in patients with attention deficit hyperactivity disorder (ADHD), which is considered as an endophenotype of ADHD. Genetic study of inhibitory control could advance gene discovery and further facilitate the understanding of ADHD genetic basis, but the studies were limited in both the general population and ADHD patients. To reveal genetic risk variants of inhibitory control and its potential genetic relationship with ADHD, we conducted genome-wide association studies (GWAS) on inhibitory control using three datasets, which included 783 and 957 ADHD patients and 1350 healthy children. Subsequently, we employed polygenic risk scores (PRS) to explore the association of inhibitory control with ADHD and related psychiatric disorders. Firstly, we identified three significant loci for inhibitory control in the healthy dataset, two loci in the case dataset, and one locus in the meta-analysis of three datasets. Besides, we found more risk genes and variants by applying transcriptome-wide association study (TWAS) and conditional FDR method. Then, we constructed a network by connecting the genes identified in our study, leading to the identification of several vital genes. Lastly, we identified a potential relationship between inhibitory control and ADHD and autism by PRS analysis and found the direct and mediated contribution of the identified genetic loci on ADHD symptoms by mediation analysis. In conclusion, we revealed some genetic risk variants associated with inhibitory control and elucidated the benefit of inhibitory control as an endophenotype, providing valuable insights into the mechanisms underlying ADHD.
Symptoms associated with discontinuation of PAXIL have been reported (see PRECAUTIONS: Discontinuation of Treatment With PAXIL). Patients should be monitored for these symptoms when discontinuing treatment, regardless of the indication for which PAXIL is being prescribed. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.

NOTE: SHAKE SUSPENSION WELL BEFORE USING.